Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Shares Issued (2023 - 2025)

Historic Shares Issued for Contineum Therapeutics (CTNM) over the last 3 years, with Q2 2025 value amounting to $243000.0.

  • Contineum Therapeutics' Shares Issued fell 2186.5% to $243000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $108.3 million, marking a year-over-year increase of 20069.72%. This contributed to the annual value of $108.2 million for FY2024, which is 6795723.27% up from last year.
  • Per Contineum Therapeutics' latest filing, its Shares Issued stood at $243000.0 for Q2 2025, which was down 2186.5% from $24000.0 recorded in Q1 2025.
  • In the past 5 years, Contineum Therapeutics' Shares Issued ranged from a high of $108.1 million in Q4 2024 and a low of -$108.1 million during Q3 2024
  • Moreover, its 3-year median value for Shares Issued was $66000.0 (2023), whereas its average is $85900.0.
  • Within the past 5 years, the most significant YoY rise in Contineum Therapeutics' Shares Issued was 21602600.0% (2024), while the steepest drop was 13188414.63% (2024).
  • Contineum Therapeutics' Shares Issued (Quarter) stood at $50000.0 in 2023, then skyrocketed by 216026.0% to $108.1 million in 2024, then plummeted by 99.78% to $243000.0 in 2025.
  • Its last three reported values are $243000.0 in Q2 2025, $24000.0 for Q1 2025, and $108.1 million during Q4 2024.